secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2025-12-19T23:59:59+00:00
Accession:  0001193125-25-325856
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin to acquire Amicus Therapeutics for $4.8B in all-cash deal at $14.50/share
--------------------------------------------------------------------------------

- BioMarin acquires Amicus for $14.50/share in cash, total equity value ~$4.8B; expected Q2 2026 close.
- Acquisition adds Galafold (Fabry) and Pombiliti+Opfolda (Pompe) products; Amicus's trailing 12-month revenue $599M.
- BioMarin secures up to $3.65B bridge loan from Morgan Stanley to fund transaction.
- Deal expected to be accretive to Non-GAAP diluted EPS in first 12 months post-close, substantially accretive from 2027.
- Amicus board unanimously recommends; subject to Amicus stockholder approval and regulatory clearances.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000119312525325856/0001193125-25-325856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000119312525325856/d49247d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-325856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer